Send to

Choose Destination
Arthritis Care Res (Hoboken). 2019 Sep 9. doi: 10.1002/acr.24066. [Epub ahead of print]

The Accelerating Medicines Partnership - Organizational Structure and Preliminary Data from the Phase 1 Studies of Lupus Nephritis.

Author information

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Division of Rheumatology and Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
Internal Medicine, Department of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rheumatology Division and Russell/Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA.
Center for Autoimmune, Musculoskeletal and Hematologic Diseases, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, USA.


The Accelerating Medicines Partnership (AMP) Lupus Network was established as a partnership between the NIH, pharmaceutical companies, non-profit stakeholders and lupus investigators across multiple academic centers to apply high throughput technologies to the analysis of renal tissue, urine and blood from patients with lupus nephritis (LN). The AMP network provides publicly accessible data to the community with the goal of generating new scientific hypotheses and improving diagnostic and therapeutic tools so as to improve disease outcomes. We present here a description of the structure of the AMP Lupus Network and a summary of the preliminary results from the Phase 1 studies. The successful completion of Phase 1 sets the stage for analysis of a large cohort of LN samples in Phase 2 and provides a model for establishing similar discovery cohorts.


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center